Canaloplasty in the Treatment of Uveitic Glaucoma – Results of an 18-Month Follow-up

Canaloplasty in the Treatment of Uveitic Glaucoma – Results of an 18-Month Follow-up | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Canaloplasty in the Treatment of Uveitic Glaucoma – Results of an 18-Month Follow-up Monika Łazicka-Gałecka, Anna Kamińska, Monika Popowska, Tomasz Gałecki, and 3 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8603369/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Introduction: Uveitic glaucoma (UG) is a type of secondary glaucoma in which elevated intraocular pressure (IOP) and subsequent optic nerve damage result from a chronic inflammation of the uvea. UG is estimated to occur in approximately 20% of patients with uveitis. Due to its complex etiology UG treatment requires a highly personalized approach. In recent years, minimally invasive glaucoma surgery (MIGS) procedures, such as canaloplasty (CP), have gained recognition for their potential to effectively reduce IOP while minimizing complications associated with traditional filtration surgeries. The aim of this study was to evaluate the efficacy and safety of canaloplasty in patients with UG. Materials and Methods: This prospective study included 15 eyes with UG that received 360° ab externo canaloplasty. The main indication for surgery was the failure of maximum tolerated medical therapy. Control check-ups were conducted pre-operatively and in an 18-month follow-up time. Study endpoints involved reduction in IOP values and in the number of glaucoma medications after the intervention. Results: CP led to a significant 64 % reduction in IOP (14.44 ± 3.54 mmHg) from the preoperative baseline. The number of medications decreased significantly by 94%. Complete success (IOP < 18 mmHg) was achieved in 84% of patients, while qualified success (IOP < 21 mmHg) was observed in 92%. No severe complications were reported. The most common postoperative findings were microhyphema (46.1%) and cataract formation (23%). A recurrence of uveitis was noted in two cases (15.3%) but was successfully managed. Flare photometry measurements indicated a significant reduction in intraocular inflammation postoperatively. Conclusions: Canaloplasty proved to be an effective and safe surgical option for UG patients. Canaloplasty Non-penetrating glaucoma surgery Uveitic glaucoma Schlemm’s canal surgery Figures Figure 1 Introduction Uveitic glaucoma (UG) is a type of secondary glaucoma in which elevated intraocular pressure (IOP) and subsequent optic nerve damage arise from an ongoing inflammatory process in the uvea [ 1 ]. It is estimated that UG occurs in approximately 20% of patients with uveitis [ 2 ]. Chronic or recurrent forms of uveitis lead to UG more frequently than the acute. Depending on the affected part of the uvea, inflammatory glaucoma is the most common among patients with anterior uveitis (AU), slightly less frequent in those with panuveitis. It is rare in those with posterior or intermediate uveitis [ 3 , 4 ]. The incidence of UG also depends on the underlying etiology of uveitis. It most commonly develops in the course of herpetic uveitis, toxoplasmosis and syphilis. Patients with Fuchs’ Heterochromic Uveitis (FHU), Posner-Schlossman syndrome (PS), sarcoidosis, juvenile idiopathic arthritis (JIA), Behçet’s disease, Vogt-Koyanagi-Harada disease or sympathetic ophthalmia are of greater risk [ 2 ]. The distinguishing features of UG include a younger patient age, more pronounced IOP fluctuations, challenges in obtaining high-quality imaging, episodes of hypotony, worse response to IOP-lowering medications, more rapid progression leading to severe optic nerve damage, and a higher risk of complications following traditional glaucoma surgeries [ 5 ]. Due to the heterogeneous etiology of IOP rise and glaucoma among patients with uveitis, there is no standardized therapeutic protocol. Each case requires an individual approach. It is important to note that glaucoma secondary to inflammatory disease cannot be treated independently of the underlying cause. The foundation of treatment is the rapid and effective management of inflammation, with corticosteroids being the first choice for induction therapy. To reduce IOP, both pharmacological and surgical methods are employed [ 6 ]. Pharmacotherapy is the first-line treatment for elevated IOP, and if it is not effective, surgical intervention is required. Studies suggest that approximately 30% of patients with UG will require surgical treatment. It is known that glaucoma surgery in eyes with uveitis carries a higher risk of failure and a greater incidence of complications in comparison to eyes without inflammation [ 8 , 9 ]. Effective control of the inflammation prior to surgery significantly improves surgical success rates and reduces complication rates. Trabeculectomy is traditionally considered the first-line surgical option for UG. Its success depends on the proper function of the filtering bleb [ 10 , 11 , 12 ]. It has been shown that the conjunctiva of patients with UG contains significantly more fibroblasts, lymphocytes, and macrophages than the conjunctiva of patients with primary open-angle glaucoma (POAG), which increases the risk of faster fistula closure in these patients [ 13 ]. The study by Souissi et al., which evaluated the five-year outcomes of trabeculectomy without the use of antimetabolites in patients with UG, confirmed that the procedure effectively lowers IOP in the majority of UG patients. 45.5% achieved complete success and 54.5% achieved qualified success. However, the results of the procedure in this group were inferior to those reported in the literature for POAG patients [ 14 ]. Kaburaki et al. demonstrated that patients with UG who undergo trabeculectomy face a significantly higher risk of serious postoperative complications—particularly persistent hypotony—than individuals with POAG [ 15 ]. In recent years, non-perforating procedures and MIGS (minimally invasive glaucoma surgery) have been increasingly popular in UG, given their improved safety profile compared with traditional filtering surgery [ 17 , 18 , 19 ]. It is well known that chronically elevated IOP in patients with uveitis can be a result of excessive extracellular matrix (ECM) accumulation within the trabecular meshwork (TM), leading to reduced elasticity and narrowing of the intertrabecular spaces. Corticosteroids similarly contribute to pathological TM changes [ 20 ]. Canaloplasty (CP), by removing these altered structures, may reverse the underlying cause of UG and restore the physiological mechanisms of aqueous outflow. Notably, ab externo CP does not require the opening of the anterior chamber or incision of the iris, thus minimizing surgery-induced inflammation and lowering the risk of reactivation of the primary disease. Furthermore, the Descemet’s window serves as a natural barrier against excessive filtration, protecting against hypotony and its related complications, such as maculopathy and choroidal detachment [ 21 , 22 , 23 ]. Materials and Methods This was a prospective study without a control group conducted at the Department of Ophthalmology of Medical University of Warsaw. All patients signed a consent form prior to undergoing the procedure. The study was conducted in accordance with the Declaration of Helsinki A total of 15 eyes (6 right eyes, 9 left eyes) from 13 patients (8 men and 5 women) with UG were included in the study. All patients were treated by the same uveitis specialist. The underlying disease was anterior uveitis in 13 eyes and intermediate uveitis in 2 eyes. The detailed etiology of uveitis is presented in Table 1. Table 1. Etiology of uveitis in study group. PP – pars planitis. CMV -Cytomegalovirus Type of uveitis FHU HLA B27 (+) PS PP JIA CMV AU Idiopathic AU Number of Eyes 4 4 2 2 1 1 1 The indication for surgery in all patients was the inability to achieve IOP normalization despite maximal tolerated medical therapy (MTMT). In 10 eyes , the procedure was performed as an emergency intervention, while in 5 eyes , the surgery was elective. Due to the urgency of the surgical intervention, the interval from the last episode of acute anterior uveitis (AAU) was less than 3 months, with a mean of 73 ± 67.1 days (range: 2–205 day s). At the time of surgical qualification 8 patients were receiving oral corticosteroid therapy; 6 of these patients were also on systemic immunosuppression (mycophenolate mofetil , methotrexate, or adalimumab); 6 patients were using topical corticosteroids. At the time of the surgery, no active inflammation was observed. Preoperative flare photometry measurements averaged 18.03 ± 6.16 (range: 7.3–26.0). Although this value is above the normal range, it is considered typical finding in patients with uveitis, where chronic blood-aqueous barrier (BAB) dysfunction is commonly present. The mean IOP was 42.76 ± 9.82 mmHg (range: 28–58 mmHg). The mean number of topical medications used per patient was 3.55 ± 0.74 (range: 2–4). Each patient was receiving the MTMT. 4 patients using 3 medications were not prescribed prostaglandin inhibitors (PGI), including 3 patients with a history of cystoid macular edema (CME) and 1 patient with cytomegalovirus-associated AAU. 1 patient using 2 medications had contraindications to PGI (history of CME) and beta-blockers (left bundle branch block). 12 patients (14 eyes) were also receiving systemic acetazolamide at a dose of 250 mg bid. Regarding lens status, 11 eyes were phakic, while 4 eyes were pseudophakic. Table 2. Data of patients included in the study. Variable Mean ± SD Range Age (years) 31,60 ±8,51 17-45 Female sex 34 (51%) - OP (%) 31 (46%) - c/d 0,73 ±0,15 0,4-0,9 Shaffer angle grading 3,19 ±0,69 2-4 Visual field, MD 5,72 ± 2,49 w. 3,1 – 10,8 The remaining data of patients included in the study are presented in Table 2. The inclusion and exclusion criteria for the procedure are presented in Table 3. Table 3. Inclusion and exclusion criteria for the procedure. The patients were examined preoperatively and on postoperative day 1 and 7, and at 1, 3, 6, 9, and 12 months after surgery. A comprehensive ophthalmic examination was performed at each follow-up visit: BCVA and IOP were measured using a Goldmann applanation tonometer. The IOP measurement was recorded as the mean of 2 readings taken 10 minutes apart if the difference between them was ≤ 2 mmHg. If the difference was ≥ 3 mmHg, a third measurement was performed, and the final value was calculated as the average of all three readings, following the recommendations of the Guidelines on Design and Reporting of Glaucoma Surgical Trials (2009). Additionally, a record was maintained of the number and type of antiglaucoma medications used, as well as any postoperative complications. Study Endpoints: Efficacy of CP in the treatment of UG measured by total success (TS) – achieving IOP < 18 mmHg or IOP < 21 mmHg without the use of antiglaucoma medications, and qualified success (QS) – achieving IOP < 18 mmHg or IOP < 21 mmHg with the need for antiglaucoma medications. Reduction of IOP compared to the preoperative period Reduction in the number of antiglaucoma medications Flare photometry measurement Postoperative complications registry Surgical Technique All patients underwent 360° ab externo CP with the placement of a tension suture. Surgery was performed under local anesthesia, consisting of peribulbar anesthesia combined with short intravenous sedation. The mean surgical time was 36.07 ± 5.2 minutes (range: 28–44 minutes). The postoperative topical treatment regimen is presented in Table 4. Table 4. Post-CP treatment regimen. Medication Dosage frequency Duration of therapy Levofloxacin 4 times per day (qid) 7 days Dexamethasone 4 times per day (qid) 4 – 12 weeks, depending on examination Systemic treatment with corticosteroids (CS) and immunomodulatory therapy (IMT) was continued at preoperative doses. Demographic data (age, sex) as well as baseline ophthalmic parameters were described using the mean, standard deviation, and median for continuous variables, and absolute and relative frequencies for categorical variables. The Shapiro-Wilk test was applied to assess the normality of the data distribution. The baseline characteristics of patients with different types of glaucoma were compared using Pearson's chi-square test for categorical variables such as sex and right and left eye. To assess repeated measurements, such as IOP, best corrected visual acuity (BCVA), and the number of antiglaucoma medications taken at different time points, the Wilcoxon signed-rank test was used. The Kaplan–Meier survival analysis was used to assess the probability of time without the need for antiglaucoma medications. The log-rank test was applied to analyze differences in survival curves among the three types of glaucoma. The analyses were conducted using Statistica software, version 13.3 . Results To obtain the most reliable results, the analysis included 13 eyes. One eye from each of the two bilaterally operated patients was excluded. The eye included in the study was the first operated eye. Efficacy of CP in lowering IOP The preoperative mean IOP in the group of 13 eyes was 40.53 ± 9.34 mmHg (range: 28–58 mmHg). On the first postoperative day, the mean IOP decreased by 65% to 14.07 ± 2.43 mmHg. The Wilcoxon signed-rank test for repeated measurements demonstrated a statistically significant reduction in IOP between the preoperative values and each follow-up examination. Table 5 presents the mean IOP and the reduction from preoperative values at all study time points. Figure 1 shows the distribution of preoperative IOP and IOP at the end of the observation. Table 5 Mean IOP and reduction from preoperative values. Comparison of preoperative and postoperative IOP using the Wilcoxon signed-rank test. Statistically significant p-values are highlighted in red. IOP Mean Min. Max. SD ↓IOP in % p pre 40,53 28 58 9,34 x x 1d 14,07 10 18 2,43 65 0,0006 7d 13,67 10 17 2,19 66 0,0006 1m 13,13 1 17 1,92 67 0,0006 3m 13,73 11 22 2,74 66 0,0006 6m 13,73 11 22 2,87 66 0,0006 9m 13,67 11 19 2,38 66 0,0006 1y 13,40 11 15 1,43 66 0,005 1,5y 14,44 11 23 3,54 64 0,007 Efficacy of CP in reducing the number of medications in UG Before surgery, the mean number of topical antiglaucoma medications in the group of 13 analyzed eyes was 3.6 ± 0.63 (range: 2–4). Additionally, 12 patients (92.3%) were receiving oral acetazolamide. Following surgery, there was a significant reduction in the number of medications used. During the first 3 months, none of the patients required topical antiglaucoma therapy. At the 6 months follow-up, one patient experienced an IOP increase (where goniopuncture was ineffective) and required the initiation of IOP-lowering eye drops. This patient used one medication between 6 and 12 months postoperatively. After one year, another IOP elevation was noted, and from the 14th postoperative month, the patient required two antiglaucoma medications. At the 18-month visit, IOP in this patient reached 22 mmHg, necessitating the addition of a third medication. The postoperative reduction in the number of medications was statistically significant at each stage of the study. Table 6 presents the mean number of medications used at each follow-up visit, along with the Wilcoxon signed-rank test results comparing preoperative and postoperative number of medications. Table 6 Mean number of antiglaucoma eye drops used, reduction in medication use, comparison of medication count before and after CP using the Wilcoxon test. Statistically significant p-values are marked in red. Eye drops Mean Min. Max SD ↓% p pre 3,60 2,00 4,00 0,63 x x 1d - - - - 100 0,000655 7d - - - - 100 0,000655 1m - - - - 100 0,000655 3m - - - - 100 0,000655 6m 0,07 - 1,00 0,26 98 0,000655 9m 0,07 - 1,00 0,26 98 0,000655 1y 0,09 - 1,00 0,30 97,5 0,003346 1,5y 0,20 - 2,00 0,63 94 0,005062 Success of CP in the Treatment of UG At 18th month, 84% of patients achieved TS, that was predefined as IOP of < 18 mmHg, while 92% of patients obtained IOP < 21 mmHg. QS for IOP thresholds was observed in 92% of patients. TS and QS are presented in the Table 7 . Table 7 TS and QS at different stages of the study. Time since surgery Success < 18 mmHg Succes < 21mmHg Total Qualified Total Qualified n % n % n % n % 1 d. 12 92 12 92 13 100 13 100 7 d. 13 100 13 100 13 100 13 100 1 m. 13 100 13 100 13 100 13 100 3 m. 12 92 12 92 12 92 12 92 6 m. 12 92 12 92 12 92 13 100 9 m. 12 92 12 92 12 92 12 92 1y 11 84 12 92 12 92 12 92 1,5y 11 84 12 92 12 92 12 92 Frequency of postoperative complications in UG No intraoperative complications were observed. There were no vision-threatening complications such as hypotony or choroidal detachment. The most observed postoperative findings in the early days following surgery were microhyphema and hyphema, which occurred in 8 eyes (46.1%). This is considered to be a result of blood reflux from the episcleral veins into Schlemm’s canal, a favorable prognostic sign indicating the patency of distal aqueous outflow pathways from the canal. Cataract development was noted in 3 patients (23%). However, it should be emphasized that this complication may result from the combined effects of the surgical procedure and the prolonged use of both topical and systemic corticosteroids. Additionally, in the baseline examination, phakic patients exhibited signs of lens opacification. Recurrence of uveitis was observed in 2 cases. In one patient with HLA-B27 positivity, a relapse occurred 11 months after surgery, following the discontinuation of adalimumab 6 weeks earlier due to ankylosing spondylitis. In another patient, a recurrence of pars planitis was noted 14 months postoperatively. In both cases, remission was successfully achieved with the standard treatment. Spearman's rank correlation analysis did not reveal any association between the occurrence of hyphema, cataract formation, or uveitis recurrence and higher IOP values or the need for antiglaucoma medications. The frequency of complications following CP is presented in Table 8 . Table 8 List of postoperative complications identified during the study. Complication n Percentage Microhyphema 6 46,1 ↑ IOP > 21 mmHg 3 23,0 Cataract 3 23,0 Recurrence of UV 2 15,3 Hyphema 2 15,3 Flare photometry results after CP In patients who underwent CP, a statistically significant reduction in mean flare photometry values was observed, when compared to preoperative levels. Preoperative flare photometry values showed a strong positive correlation with preoperative IOP values, as indicated by Spearman’s rank correlation coefficient (r = 0.811). However, no such correlation was found between flare photometry and postoperative IOP. Table 9 presents the flare photometry results before and after CP. Table 9 Mean flare photometry in UG. Comparison of preoperative and postoperative values using the Wilcoxon test. Flare photometry Mean Min. Max. SD Wilcoxon signed-rank test Pairs n z p Pre 18,03 7,30 26,00 6,16 - - - - 1m 10,25 6,90 15,30 2,29 1m & pre 13 3,18 0,0015 3m 9,77 5,20 15,10 2,60 3m & pre 13 3,12 0,0018 6m 9,73 6,10 16,00 2,66 6m & pre 13 3,41 0,0007 Discussion As previously mentioned, UG is particularly challenging to manage due to the necessity of simultaneous treatment of the underlying inflammatory disease. Rapid and effective control of intraocular inflammation is key to achieving successful outcomes. However, this remains difficult, as corticosteroids, which are the mainstay of anti-inflammatory therapy, can contribute to the increase in IOP. Chronic disruption of the BAB, commonly observed in this patient’s population, not only increases the risk of postoperative complications, but may also contribute to the late surgical failure, for instance, due to excessive scarring. For these reasons, in recent years, there has been an increasing shift towards MIGS, particularly bleb-less procedures, in the treatment of UG [ 24 , 25 ]. The conducted study confirmed the high efficacy of CP in the treatment of UG, with the mean IOP reduction of 66% and 64% at 12 and 18 months postoperatively, respectively. Throughout the entire follow-up period, only 1 patient required an introduction of IOP-lowering therapy. This patient had the longest diagnosis of both UG and the underlying systemic disease within the study group. At 1.5 years postoperatively, 84% of patients achieved TS for IOP < 21 mmHg and IOP < 18 mmHg. CP also proved to be a safe surgical approach for UG management. No sight-threatening complications were recorded. Hyphema or microhyphema were observed in 61.4% of patients on the first postoperative day. As demonstrated by Grieshaber et al. in their 2011 study, the presence of hyphema shortly after canaloplasty correlates with greater long-term surgical success and should not be considered a complication [ 26 ]. The cumulative probability of achieving IOP ≤ 16 mmHg without the need for medication was 87% (95% CI; 0.76–0.98) in patients who developed microhyphema/hyphema on the first postoperative day, compared to only 21% (95% CI; 0.04–1.0) in patients whose anterior chamber remained clear. Additionally, patients with intraoperative or early postoperative hyphema/microhyphema were less likely to require goniopuncture during follow-up. Cataract development or its progression was observed in 23% of patients. Although the chronic use of corticosteroids played a significant role in the development of this complication, its incidence was notably lower than that reported after filtering surgeries. For comparison, the Advanced Glaucoma Intervention Study (AGIS) found that the risk of cataract progression following trabeculectomy was 78% [ 27 ]. Similarly, in the study by Mills et al., 45% of all cataract cases occurred within the first 6 months postoperatively [ 28 ]. Husain et al. demonstrated that cataract surgery after trabeculectomy increases the risk of glaucoma surgery failure, with the risk being higher when the interval between trabeculectomy and cataract surgery is shorter. If cataract surgery was performed within 6 months after trabeculectomy, the risk of failure for the latter was 3.00 (95% CI; 1.11–8.14). In contrast, when the interval between procedures was extended to 2 years, the risk decreased to 1.32 (95% CI; 1.02–1.69) [ 29 ]. The incidence of uveitis recurrence after surgery was not higher than before the procedure. During the study, recurrence was observed in 2 patients. No patient showed signs of uveitis within the first 11 months postoperatively. The procedure even led to a statistically significant reduction in the mean flare photometry values compared to preoperative levels. The type of uveitis did not appear to influence surgical outcomes. UG is a rare condition with a heterogeneous etiology, which is why there is no standardized therapeutic protocol, and each case requires an individual approach. Due to this variability, there are only a few studies evaluating the effectiveness of different treatment approaches in this type of glaucoma. This study, which includes 13 eyes, is one of the largest assessing CP outcomes in UG. Lommatzsch et al. retrospectively evaluated the efficacy of CP in 12 eyes with UG. 2 years after surgery, the mean IOP reduction was 46.4%, accompanied by a 77% reduction in the number of antiglaucoma medications. No statistically significant differences in flare photometry measurements were observed between preoperative values and those recorded 1 month postoperatively. However, at 3 months postoperatively, a decrease in flare photometry was noted, which then remained stable up to 12 months [ 30 ]. TS rate for IOP ≤ 21 mmHg at 2 years after surgery was 58%, which was lower than in our study (87.5%). This difference may be attributed to the differences in patient profiles between the studies. In the study by Lommatzsch et al., most of included eyes had idiopathic uveitis, with some previously operated cases, and a mean UG duration twice as long as in the present study (52.4 ± 47.6 months vs. 24.47 ± 27.39 months) [ 30 ]. In the current study, the most frequent diagnoses were HLA-B27 (+) uveitis and FHU. Also, only previously unoperated eyes were included. In another study, Brusini et al. evaluated CP outcomes in 9 eyes with steroid-induced glaucoma (SIG). None of the patients had uveitis; steroid therapy was administered due to severe allergy or as prophylaxis against graft rejection following keratoplasty. At 1 year postoperatively, the mean IOP decreased by 55%, while the number of antiglaucoma eye drops was reduced by 95.3%. Additionally, 100% of the eyes achieved TS for both predefined IOP thresholds (≤ 21 mmHg and ≤ 16 mmHg). The most common complication was microhyphema, occurring in 22% of eyes. 1 eye experienced transient hypotony, but IOP returned to normal within 1 week, without any intervention and without any negative impact on the final BCVA [ 31 ]. Kalin-Hajdu et al. analised phaco-CP (5 eyes) and CP (8 eyes) in 9 patients with UG. At 2.5 years postoperatively, 84.2% of patients achieved IOP control, defined as IOP > 6 mmHg and < 21 mmHg, along with a minimum 20% reduction from the baseline values. Among these, 73.7% of patients did not require pharmacologic treatment. The mean IOP reduction was 55.9%, accompanied by a 94.4% reduction in the number of antiglaucoma medications. Goniopuncture was required in 42.1% of cases. The authors recorded 1 case of prolonged hypotony with hypotonic maculopathy following goniopuncture; however, all other complications were transient and did not pose a threat to vision [ 32 ]. A comparative summary of the studies evaluating the efficacy of CP in UG and SIG is presented in Table 10 . Table 10 Efficacy of CP in UG and SIG. Lommatzsch 2016 [ 30 ] Brusini 2018 [ 31 ] n 12 7 Type of glaucoma UG SIG IOP pre 27.0 ± 12.2 30.7 ± 7.2 ↓ IOP % 1y 39 55 2y 46 45 Pre med 2.7 ± 1.1 4.3 ± 0.7 ↓med.% 1y - 95.3 2y 77.8 - TS ≤ 21 1y - 100 2y 58 100 TS ≤ 18 1y - - 2y 72 - TS ≤ 15 1y - 100 2y - 100 Complications Cataract 6,4 - Hyphema 33 22 ↑ IOP - 11 WTR astigmatism - 11 Hypotony 25 11 Descemet detachment - - Summary The conducted study confirmed the efficacy of canaloplasty in the treatment of UG. The procedure leads to a significant reduction in IOP and the number of antiglaucoma medications required postoperatively. Furthermore, canaloplasty has been shown to be a safe procedure, with postoperative complications being transient and not posing a threat to the patient’s vision. Canaloplasty appears to be a promising therapeutic alternative for the patients with UG. However, the presence of an open angle without anterior synechiae is a prerequisite for performing the procedure. The limitations of this study include its single-center design, lack of randomization, small sample size, and relatively short follow-up period. Declarations Author Contribution M.Ł-G and M.P prepared the draft of the manuscriptA.K and T.G were responsible for data acquisition and interpretationM.G and J.D were responsible for data analysisM.P and J.D prepared figuresA.K and JP.S reviewed the manuscript Acknowledgements None of the authors has no financial interest concerning presented subject. Clinical trial number : not applicable No Funding was received to conduct this study All patients signed a consent form prior to undergoing the procedure. The study was conducted in accordance with the Declaration of Helsinki. The study received approval of the Ethics Committee References Moorthy, R.S., et al., Glaucoma associated with uveitis. Surv Ophthalmol, 1997. 41(5): p. 361-94. Munoz-Negrete, F.J., et al., Current Approach in the Diagnosis and Management of Uveitic Glaucoma. Biomed Res Int, 2015. 2015: p. 742792. Neri, P., A. Azuara-Blanco, and J.V. Forrester, Incidence of glaucoma in patients with uveitis. J Glaucoma, 2004. 13(6): p. 461-5. Sung, V.C. and K. Barton, Management of inflammatory glaucomas. Curr Opin Ophthalmol, 2004. 15(2): p. 136-40. Daniel, E., et al., Risk of Ocular Hypertension in Adults with Noninfectious Uveitis. Ophthalmology, 2017. 124(8): p. 1196-1208. Fini, M.E., et al., Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res, 2017. 56: p. 58-83. Feiner, L., J.R. Piltz-Seymour, and S. Collaborative Initial Glaucoma Treatment, Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol, 2003. 14(2): p. 106-11. Meier-Gibbons, F., M.S. Berlin, and M. Toteberg-Harms, Influence of new treatment modalities on adherence in glaucoma. Curr Opin Ophthalmol, 2019. 30(2): p. 104-109. Musch, D.C., et al., Visual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors. Ophthalmology, 2009. 116(2): p. 200-7. Yamanaka, O., et al., Pathobiology of wound healing after glaucoma filtration surgery. BMC Ophthalmol, 2015. 15 Suppl 1: p. 157. Gedde, S.J., et al., Treatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 3 Years of Follow-up. Ophthalmology, 2020. 127(3): p. 333-345. Gedde, S.J., et al., Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol, 2012. 153(5): p. 789-803 e2. Yamanaka, O., et al., Pathobiology of wound healing after glaucoma filtration surgery. BMC Ophthalmol, 2015. 15 Suppl 1: p. 157. Souissi, K., et al., [Trabeculectomy for the management of uveitic glaucoma]. J Fr Ophtalmol, 2006. 29(2): p. 153-6. Kaburaki, T., et al., Initial trabeculectomy with mitomycin C in eyes with uveitic glaucoma with inactive uveitis. Eye (Lond), 2009. 23(7): p. 1509-17. Matlach, J., et al., Trabeculectomy versus canaloplasty (TVC study) in the treatment of patients with open-angle glaucoma: a prospective randomized clinical trial. Acta Ophthalmol, 2015. 93(8): p. 753-61. Netland, P.A., et al., Randomized, prospective, comparative trial of EX-PRESS glaucoma filtration device versus trabeculectomy (XVT study). Am J Ophthalmol, 2014. 157(2): p. 433-440 e3. Nouri-Mahdavi, K., et al., Outcomes of trabeculectomy for primary open-angle glaucoma. Ophthalmology, 1995. 102(12): p. 1760-9. Wagner, F.M., et al., Efficacy and safety of XEN(R)-Implantation vs. trabeculectomy: Data of a "real-world" setting. PLoS One, 2020. 15(4): p. e0231614. Bull, H., et al., Three-year canaloplasty outcomes for the treatment of open-angle glaucoma: European study results. Graefes Arch Clin Exp Ophthalmol, 2011. 249(10): p. 1537-45. Brusini, P., Canaloplasty in open-angle glaucoma surgery: a four-year follow-up. ScientificWorldJournal, 2014. 2014: p. 469609. Liu, H., et al., Safety and efficacy of canaloplasty versus trabeculectomy in treatment of glaucoma. Oncotarget, 2017. 8(27): p. 44811-44818. Vastardis, I., et al., Estimation of risk-benefit ratio and comparison of post-operative efficacy results between trabeculectomy and canaloplasty. Eur J Ophthalmol, 2021. 31(3): p. 1405-1412. Watson, P.G., et al., The complications of trabeculectomy (a 20-year follow-up). Eye (Lond), 1990. 4 ( Pt 3): p. 425-38. Szymor J, J.P., Flaremetry measurement of blood-aqueousbarrier breakdown after canaloplasty combined with phacoemulsification versus phacoemulsification in patients with secondary open angle glaucoma. Klinika oczna/Acta Ophthalmologica Polonica, 2018. 120(3): p. 133-138. Grieshaber, M.C., et al., Postoperative microhyphema as a positive prognostic indicator in canaloplasty. Acta Ophthalmol, 2013. 91(2): p. 151-6. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000 Oct;130(4):429-40 Mills, K.B., Trabeculectomy: a retrospective long-term follow-up of 444 cases. Br J Ophthalmol, 1981. 65(11): p. 790-5. Husain, R., et al., Cataract surgery after trabeculectomy: the effect on trabeculectomy function. Arch Ophthalmol, 2012. 130(2): p. 165-70. Lommatzsch, C., et al., Canaloplasty in patients with uveitic glaucoma: a pilot study. Graefes Arch Clin Exp Ophthalmol, 2016. 254(7): p. 1325-30. Brusini, P., C. Tosoni, and M. Zeppieri, Canaloplasty in Corticosteroid-Induced Glaucoma. Preliminary Results. J Clin Med, 2018. 7(2). Kalin-Hajdu, E., et al., Outcome of viscodilation and tensioning of Schlemm's canal for uveitic glaucoma. Can J Ophthalmol, 2014. 49(5): p. 414-9 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8603369","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":577418916,"identity":"ca5f3e82-5773-46f0-b587-e783ac51cbde","order_by":0,"name":"Monika Łazicka-Gałecka","email":"","orcid":"","institution":"Medical University of Warsaw","correspondingAuthor":false,"prefix":"","firstName":"Monika","middleName":"","lastName":"Łazicka-Gałecka","suffix":""},{"id":577418917,"identity":"ae920edd-3645-407a-8bb4-e0d9627703cd","order_by":1,"name":"Anna Kamińska","email":"","orcid":"","institution":"Medical University of Warsaw","correspondingAuthor":false,"prefix":"","firstName":"Anna","middleName":"","lastName":"Kamińska","suffix":""},{"id":577418918,"identity":"1d8d1f6b-f17a-4191-ab0b-8819940e6243","order_by":2,"name":"Monika Popowska","email":"","orcid":"","institution":"Medical University of Warsaw","correspondingAuthor":false,"prefix":"","firstName":"Monika","middleName":"","lastName":"Popowska","suffix":""},{"id":577418919,"identity":"ac9c2bcf-420a-47b1-b0f2-f07df618ca3a","order_by":3,"name":"Tomasz Gałecki","email":"","orcid":"","institution":"Medical University of Warsaw","correspondingAuthor":false,"prefix":"","firstName":"Tomasz","middleName":"","lastName":"Gałecki","suffix":""},{"id":577418920,"identity":"8b37a976-0813-4eb0-ad97-05f20158bb27","order_by":4,"name":"Maria Guszkowska","email":"","orcid":"","institution":"Medical University of Warsaw","correspondingAuthor":false,"prefix":"","firstName":"Maria","middleName":"","lastName":"Guszkowska","suffix":""},{"id":577418921,"identity":"8ed8c292-016d-4c6b-9503-fca0db49a434","order_by":5,"name":"Jacek Dziedziak","email":"data:image/png;base64,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","orcid":"","institution":"Medical University of Warsaw","correspondingAuthor":true,"prefix":"","firstName":"Jacek","middleName":"","lastName":"Dziedziak","suffix":""},{"id":577418922,"identity":"fb12f379-9b38-46a6-8655-72252c27cb92","order_by":6,"name":"Jacek Paweł Szaflik","email":"","orcid":"","institution":"Medical University of Warsaw","correspondingAuthor":false,"prefix":"","firstName":"Jacek","middleName":"Paweł","lastName":"Szaflik","suffix":""}],"badges":[],"createdAt":"2026-01-14 15:39:03","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8603369/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8603369/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":101940855,"identity":"cb860bbf-66ed-448c-8814-b54e71364908","added_by":"auto","created_at":"2026-02-05 09:17:35","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":17388,"visible":true,"origin":"","legend":"\u003cp\u003eDistribution of preoperative and postoperative IOP at 1.5 years.\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-8603369/v1/71d893b1a82ff5dc0a0d53ee.png"},{"id":102433620,"identity":"59058e4b-aa3e-41bb-97a3-e0f8a925844a","added_by":"auto","created_at":"2026-02-11 15:42:23","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":968523,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8603369/v1/39eb752a-483a-47a9-bd2a-11fa620ac87d.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Canaloplasty in the Treatment of Uveitic Glaucoma – Results of an 18-Month Follow-up","fulltext":[{"header":"Introduction","content":"\u003cp\u003eUveitic glaucoma (UG) is a type of secondary glaucoma in which elevated intraocular pressure (IOP) and subsequent optic nerve damage arise from an ongoing inflammatory process in the uvea [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e]. It is estimated that UG occurs in approximately 20% of patients with uveitis [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. Chronic or recurrent forms of uveitis lead to UG more frequently than the acute. Depending on the affected part of the uvea, inflammatory glaucoma is the most common among patients with anterior uveitis (AU), slightly less frequent in those with panuveitis. It is rare in those with posterior or intermediate uveitis [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e, \u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe incidence of UG also depends on the underlying etiology of uveitis. It most commonly develops in the course of herpetic uveitis, toxoplasmosis and syphilis. Patients with Fuchs\u0026rsquo; Heterochromic Uveitis (FHU), Posner-Schlossman syndrome (PS), sarcoidosis, juvenile idiopathic arthritis (JIA), Beh\u0026ccedil;et\u0026rsquo;s disease, Vogt-Koyanagi-Harada disease or sympathetic ophthalmia are of greater risk [\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe distinguishing features of UG include a younger patient age, more pronounced IOP fluctuations, challenges in obtaining high-quality imaging, episodes of hypotony, worse response to IOP-lowering medications, more rapid progression leading to severe optic nerve damage, and a higher risk of complications following traditional glaucoma surgeries [\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e]. Due to the heterogeneous etiology of IOP rise and glaucoma among patients with uveitis, there is no standardized therapeutic protocol. Each case requires an individual approach. It is important to note that glaucoma secondary to inflammatory disease cannot be treated independently of the underlying cause. The foundation of treatment is the rapid and effective management of inflammation, with corticosteroids being the first choice for induction therapy. To reduce IOP, both pharmacological and surgical methods are employed [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003ePharmacotherapy is the first-line treatment for elevated IOP, and if it is not effective, surgical intervention is required. Studies suggest that approximately 30% of patients with UG will require surgical treatment. It is known that glaucoma surgery in eyes with uveitis carries a higher risk of failure and a greater incidence of complications in comparison to eyes without inflammation [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e, \u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e]. Effective control of the inflammation prior to surgery significantly improves surgical success rates and reduces complication rates. Trabeculectomy is traditionally considered the first-line surgical option for UG. Its success depends on the proper function of the filtering bleb [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. It has been shown that the conjunctiva of patients with UG contains significantly more fibroblasts, lymphocytes, and macrophages than the conjunctiva of patients with primary open-angle glaucoma (POAG), which increases the risk of faster fistula closure in these patients [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe study by Souissi et al., which evaluated the five-year outcomes of trabeculectomy without the use of antimetabolites in patients with UG, confirmed that the procedure effectively lowers IOP in the majority of UG patients. 45.5% achieved complete success and 54.5% achieved qualified success. However, the results of the procedure in this group were inferior to those reported in the literature for POAG patients [\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eKaburaki et al. demonstrated that patients with UG who undergo trabeculectomy face a significantly higher risk of serious postoperative complications\u0026mdash;particularly persistent hypotony\u0026mdash;than individuals with POAG [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIn recent years, non-perforating procedures and MIGS (minimally invasive glaucoma surgery) have been increasingly popular in UG, given their improved safety profile compared with traditional filtering surgery [\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e, \u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eIt is well known that chronically elevated IOP in patients with uveitis can be a result of excessive extracellular matrix (ECM) accumulation within the trabecular meshwork (TM), leading to reduced elasticity and narrowing of the intertrabecular spaces. Corticosteroids similarly contribute to pathological TM changes [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e]. Canaloplasty (CP), by removing these altered structures, may reverse the underlying cause of UG and restore the physiological mechanisms of aqueous outflow. Notably, ab externo CP does not require the opening of the anterior chamber or incision of the iris, thus minimizing surgery-induced inflammation and lowering the risk of reactivation of the primary disease. Furthermore, the Descemet\u0026rsquo;s window serves as a natural barrier against excessive filtration, protecting against hypotony and its related complications, such as maculopathy and choroidal detachment [\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e, \u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e].\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cp\u003eThis was a prospective study without a control group conducted at the Department of Ophthalmology of Medical University of Warsaw. All patients signed a consent form prior to undergoing the procedure. The study was conducted in accordance with the Declaration of Helsinki\u003c/p\u003e\n\u003cp\u003eA total of\u0026nbsp;15 eyes\u0026nbsp;(6 right eyes, 9 left eyes) from\u0026nbsp;13 patients\u0026nbsp;(8 men and 5 women) with UG were included in the study. All patients were treated by the same uveitis specialist. The underlying disease was\u0026nbsp;anterior uveitis\u0026nbsp;in\u0026nbsp;13 eyes\u0026nbsp;and\u0026nbsp;intermediate uveitis\u0026nbsp;in\u0026nbsp;2 eyes. The detailed etiology of uveitis is presented in\u0026nbsp;Table 1.\u003c/p\u003e\n\u003cp\u003eTable 1. Etiology of uveitis in study group. PP \u0026ndash; pars planitis. CMV -Cytomegalovirus\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"100%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 17px;\"\u003e\n \u003cp\u003eType of uveitis\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10px;\"\u003e\n \u003cp\u003eFHU\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11px;\"\u003e\n \u003cp\u003eHLA B27 (+)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10px;\"\u003e\n \u003cp\u003ePS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10px;\"\u003e\n \u003cp\u003ePP\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10px;\"\u003e\n \u003cp\u003eJIA\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10px;\"\u003e\n \u003cp\u003eCMV AU\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16px;\"\u003e\n \u003cp\u003eIdiopathic\u0026nbsp;\u003c/p\u003e\n \u003cp\u003eAU\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 17px;\"\u003e\n \u003cp\u003eNumber of Eyes\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10px;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 11px;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10px;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 10px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16px;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eThe indication for surgery in all patients was the inability to achieve IOP normalization despite maximal tolerated medical therapy (MTMT). In \u003cstrong\u003e10 eyes\u003c/strong\u003e, the procedure was performed as an emergency intervention, while in \u003cstrong\u003e5 eyes\u003c/strong\u003e, the surgery was elective.\u003c/p\u003e\n\u003cp\u003eDue to the urgency of the surgical intervention, the interval from the last episode of acute anterior uveitis (AAU) was less than 3 months, with a mean of \u003cstrong\u003e73 \u0026plusmn; 67.1 days\u003c/strong\u003e (range: \u003cstrong\u003e2\u0026ndash;205 day\u003c/strong\u003es).\u003c/p\u003e\n\u003cp\u003eAt the time of surgical qualification 8 patients\u0026nbsp;were receiving oral corticosteroid therapy; 6 of these patients\u0026nbsp;were also on systemic immunosuppression (mycophenolate mofetil\u003cstrong\u003e,\u0026nbsp;\u003c/strong\u003emethotrexate, or adalimumab); 6 patients\u0026nbsp;were using topical corticosteroids.\u003c/p\u003e\n\u003cp\u003eAt the time of the surgery, no active inflammation was observed. Preoperative\u0026nbsp;flare photometry\u0026nbsp;measurements averaged\u0026nbsp;18.03 \u0026plusmn; 6.16\u0026nbsp;(range:\u0026nbsp;7.3\u0026ndash;26.0). Although this value is above the normal range, it is considered typical finding in patients with uveitis, where chronic blood-aqueous barrier (BAB) dysfunction is commonly present.\u003c/p\u003e\n\u003cp\u003eThe mean IOP was 42.76 \u0026plusmn; 9.82 mmHg (range: 28\u0026ndash;58 mmHg). The mean number of topical medications used per patient was 3.55 \u0026plusmn; 0.74 (range: 2\u0026ndash;4).\u003c/p\u003e\n\u003cp\u003eEach patient was receiving the MTMT. 4 patients using 3 medications were not prescribed prostaglandin inhibitors (PGI), including 3 patients with a history of cystoid macular edema (CME) and 1 patient with cytomegalovirus-associated AAU. 1 patient using 2 medications had contraindications to PGI (history of CME) and beta-blockers (left bundle branch block).\u003c/p\u003e\n\u003cp\u003e12 patients (14 eyes) were also receiving systemic acetazolamide at a dose of 250 mg bid.\u003c/p\u003e\n\u003cp\u003eRegarding lens status, 11 eyes were phakic, while 4 eyes were pseudophakic.\u003c/p\u003e\n\u003cp\u003eTable 2. Data of patients included in the study.\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"93%\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 29px;\"\u003e\n \u003cp\u003eVariable\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39px;\"\u003e\n \u003cp\u003eMean \u0026plusmn; SD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 31px;\"\u003e\n \u003cp\u003eRange\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 29px;\"\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39px;\"\u003e\n \u003cp\u003e31,60 \u0026plusmn;8,51\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 31px;\"\u003e\n \u003cp\u003e17-45\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 29px;\"\u003e\n \u003cp\u003eFemale sex\u003c/p\u003e\n \u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39px;\"\u003e\n \u003cp\u003e34 (51%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 31px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 29px;\"\u003e\n \u003cp\u003eOP (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39px;\"\u003e\n \u003cp\u003e31 (46%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 31px;\"\u003e\n \u003cp\u003e-\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 29px;\"\u003e\n \u003cp\u003ec/d\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39px;\"\u003e\n \u003cp\u003e0,73 \u0026plusmn;0,15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 31px;\"\u003e\n \u003cp\u003e0,4-0,9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 29px;\"\u003e\n \u003cp\u003eShaffer angle grading\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39px;\"\u003e\n \u003cp\u003e3,19 \u0026plusmn;0,69\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 31px;\"\u003e\n \u003cp\u003e2-4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 29px;\"\u003e\n \u003cp\u003eVisual field, MD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39px;\"\u003e\n \u003cp\u003e5,72 \u0026plusmn; 2,49 w.\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 31px;\"\u003e\n \u003cp\u003e3,1 \u0026ndash; 10,8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eThe remaining data of patients included in the study are presented in Table 2. The inclusion and exclusion criteria for the procedure are presented in Table 3.\u003c/p\u003e\n\u003cp\u003eTable 3. Inclusion and exclusion criteria for the procedure.\u003c/p\u003e\n\u003cp\u003e\u003cimg src=\"data:image/png;base64,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\"\u003e\u003c/p\u003e\n\u003cp\u003eThe patients were examined preoperatively and on postoperative day 1 and 7, and at 1, 3, 6, 9, and 12 months after surgery.\u003c/p\u003e\n\u003cp\u003eA comprehensive ophthalmic examination was performed at each follow-up visit: BCVA and IOP were measured using a Goldmann applanation tonometer. The IOP measurement was recorded as the mean of 2 readings taken 10 minutes apart if the difference between them was \u0026le; 2 mmHg. If the difference was \u0026ge; 3 mmHg, a third measurement was performed, and the final value was calculated as the average of all three readings, following the recommendations of the Guidelines on Design and Reporting of Glaucoma Surgical Trials (2009). Additionally, a record was maintained of the number and type of antiglaucoma medications used, as well as any postoperative complications.\u003c/p\u003e\n\u003cp\u003eStudy Endpoints:\u003c/p\u003e\n\u003cul\u003e\n \u003cli\u003eEfficacy of CP in the treatment of UG measured by total success (TS) \u0026ndash; achieving IOP \u0026lt; 18 mmHg or IOP \u0026lt; 21 mmHg without the use of antiglaucoma medications, and qualified success (QS) \u0026ndash; achieving IOP \u0026lt; 18 mmHg or IOP \u0026lt; 21 mmHg with the need for antiglaucoma medications.\u003c/li\u003e\n \u003cli\u003eReduction of IOP compared to the preoperative period\u003c/li\u003e\n \u003cli\u003eReduction in the number of antiglaucoma medications\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eFlare photometry measurement\u003c/li\u003e\n \u003cli\u003ePostoperative complications registry\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eSurgical Technique\u003c/p\u003e\n\u003cp\u003eAll patients underwent\u0026nbsp;360\u0026deg; ab externo CP\u0026nbsp;with the placement of a tension suture. Surgery was performed under\u0026nbsp;local anesthesia, consisting of\u0026nbsp;peribulbar anesthesia combined with short intravenous sedation. The\u0026nbsp;mean surgical time was\u0026nbsp;36.07 \u0026plusmn; 5.2 minutes\u0026nbsp;(range:\u0026nbsp;28\u0026ndash;44 minutes). The postoperative\u0026nbsp;topical treatment regimen\u0026nbsp;is presented in\u0026nbsp;Table 4.\u003c/p\u003e\n\u003cp\u003eTable 4. Post-CP treatment regimen.\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 201px;\"\u003e\n \u003cp\u003eMedication\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 201px;\"\u003e\n \u003cp\u003eDosage frequency\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 201px;\"\u003e\n \u003cp\u003eDuration of therapy\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 201px;\"\u003e\n \u003cp\u003eLevofloxacin\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 201px;\"\u003e\n \u003cp\u003e4 times per day (qid)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 201px;\"\u003e\n \u003cp\u003e7 days\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 201px;\"\u003e\n \u003cp\u003eDexamethasone\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 201px;\"\u003e\n \u003cp\u003e4 times per day (qid)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 201px;\"\u003e\n \u003cp\u003e4 \u0026ndash; 12 weeks, depending on examination\u003c/p\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eSystemic treatment with corticosteroids (CS) and immunomodulatory therapy (IMT) was continued at preoperative doses.\u003c/p\u003e\n\u003cp\u003eDemographic data (age, sex) as well as baseline ophthalmic parameters were described using the mean, standard deviation, and median for continuous variables, and absolute and relative frequencies for categorical variables. The Shapiro-Wilk test was applied to assess the normality of the data distribution.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe baseline characteristics of patients with different types of glaucoma were compared using Pearson\u0026apos;s chi-square test for categorical variables such as sex and right and left eye. To assess repeated measurements, such as IOP, best corrected visual acuity (BCVA), and the number of antiglaucoma medications taken at different time points, the Wilcoxon signed-rank test was used.\u003c/p\u003e\n\u003cp\u003eThe Kaplan\u0026ndash;Meier survival analysis was used to assess the probability of time without the need for antiglaucoma medications. The log-rank test was applied to analyze differences in survival curves among the three types of glaucoma.\u003c/p\u003e\n\u003cp\u003eThe analyses were conducted using\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003cstrong\u003eStatistica software, version 13.3\u003c/strong\u003e.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eTo obtain the most reliable results, the analysis included 13 eyes. One eye from each of the two bilaterally operated patients was excluded. The eye included in the study was the first operated eye.\u003c/p\u003e\n\u003ch3\u003eEfficacy of CP in lowering IOP\u003c/h3\u003e\n\u003cp\u003eThe preoperative mean IOP in the group of 13 eyes was 40.53\u0026thinsp;\u0026plusmn;\u0026thinsp;9.34 mmHg (range: 28\u0026ndash;58 mmHg). On the first postoperative day, the mean IOP decreased by 65% to 14.07\u0026thinsp;\u0026plusmn;\u0026thinsp;2.43 mmHg. The Wilcoxon signed-rank test for repeated measurements demonstrated a statistically significant reduction in IOP between the preoperative values and each follow-up examination. Table\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e5\u003c/span\u003e presents the mean IOP and the reduction from preoperative values at all study time points. Figure\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e shows the distribution of preoperative IOP and IOP at the end of the observation.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMean IOP and reduction from preoperative values. Comparison of preoperative and postoperative IOP using the Wilcoxon signed-rank test. Statistically significant p-values are highlighted in red.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eIOP\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMean\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMin.\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMax.\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSD\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u0026darr;IOP in %\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003ep\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003epre\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e40,53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e9,34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003ex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ex\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1d\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e14,07\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2,43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,0006\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7d\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13,67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2,19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,0006\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13,13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1,92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,0006\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13,73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2,74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,0006\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13,73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2,87\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,0006\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e9m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13,67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2,38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,0006\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13,40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1,43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,005\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1,5y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e14,44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e3,54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,007\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e\n\u003ch3\u003eEfficacy of CP in reducing the number of medications in UG\u003c/h3\u003e\n\u003cp\u003eBefore surgery, the mean number of topical antiglaucoma medications in the group of 13 analyzed eyes was 3.6\u0026thinsp;\u0026plusmn;\u0026thinsp;0.63 (range: 2\u0026ndash;4). Additionally, 12 patients (92.3%) were receiving oral acetazolamide. Following surgery, there was a significant reduction in the number of medications used.\u003c/p\u003e \u003cp\u003eDuring the first 3 months, none of the patients required topical antiglaucoma therapy. At the 6 months follow-up, one patient experienced an IOP increase (where goniopuncture was ineffective) and required the initiation of IOP-lowering eye drops. This patient used one medication between 6 and 12 months postoperatively. After one year, another IOP elevation was noted, and from the 14th postoperative month, the patient required two antiglaucoma medications. At the 18-month visit, IOP in this patient reached 22 mmHg, necessitating the addition of a third medication.\u003c/p\u003e \u003cp\u003eThe postoperative reduction in the number of medications was statistically significant at each stage of the study. Table\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e6\u003c/span\u003e presents the mean number of medications used at each follow-up visit, along with the Wilcoxon signed-rank test results comparing preoperative and postoperative number of medications.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 6\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMean number of antiglaucoma eye drops used, reduction in medication use, comparison of medication count before and after CP using the Wilcoxon test. Statistically significant p-values are marked in red.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"7\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eEye drops\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMean\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMin.\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMax\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSD\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003e\u0026darr;%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003ep\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003epre\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e3,60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2,00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4,00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0,63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003ex\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ex\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1d\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,000655\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7d\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,000655\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,000655\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,000655\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0,07\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1,00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0,26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e98\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,000655\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e9m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0,07\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1,00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0,26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e98\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,000655\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0,09\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e1,00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0,30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e97,5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,003346\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1,5y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e0,20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e2,00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e0,63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e94\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0,005062\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e\n\u003ch3\u003eSuccess of CP in the Treatment of UG\u003c/h3\u003e\n\u003cp\u003eAt 18th month, 84% of patients achieved TS, that was predefined as IOP of \u0026lt;\u0026thinsp;18 mmHg, while 92% of patients obtained IOP\u0026thinsp;\u0026lt;\u0026thinsp;21 mmHg. QS for IOP thresholds was observed in 92% of patients. TS and QS are presented in the Table\u0026nbsp;\u003cspan refid=\"Tab6\" class=\"InternalRef\"\u003e7\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab6\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 7\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eTS and QS at different stages of the study.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"2\" rowspan=\"3\"\u003e \u003cp\u003eTime since surgery\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"4\" nameend=\"c5\" namest=\"c2\"\u003e \u003cp\u003eSuccess\u0026thinsp;\u0026lt;\u0026thinsp;18 mmHg\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"4\" nameend=\"c9\" namest=\"c6\"\u003e \u003cp\u003eSucces\u0026thinsp;\u0026lt;\u0026thinsp;21mmHg\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c3\" namest=\"c2\"\u003e \u003cp\u003e\u003cb\u003eTotal\u003c/b\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c5\" namest=\"c4\"\u003e \u003cp\u003e\u003cb\u003eQualified\u003c/b\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c7\" namest=\"c6\"\u003e \u003cp\u003e\u003cb\u003eTotal\u003c/b\u003e\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c9\" namest=\"c8\"\u003e \u003cp\u003e\u003cb\u003eQualified\u003c/b\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003en\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003en\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003en\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003en\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003e%\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1 d.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7 d.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1 m.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3 m.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6 m.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e9 m.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e84\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1,5y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e84\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c8\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c9\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e\n\u003ch3\u003eFrequency of postoperative complications in UG\u003c/h3\u003e\n\u003cp\u003eNo intraoperative complications were observed. There were no vision-threatening complications such as hypotony or choroidal detachment. The most observed postoperative findings in the early days following surgery were microhyphema and hyphema, which occurred in 8 eyes (46.1%). This is considered to be a result of blood reflux from the episcleral veins into Schlemm\u0026rsquo;s canal, a favorable prognostic sign indicating the patency of distal aqueous outflow pathways from the canal.\u003c/p\u003e \u003cp\u003eCataract development was noted in 3 patients (23%). However, it should be emphasized that this complication may result from the combined effects of the surgical procedure and the prolonged use of both topical and systemic corticosteroids. Additionally, in the baseline examination, phakic patients exhibited signs of lens opacification.\u003c/p\u003e \u003cp\u003eRecurrence of uveitis was observed in 2 cases. In one patient with HLA-B27 positivity, a relapse occurred 11 months after surgery, following the discontinuation of adalimumab 6 weeks earlier due to ankylosing spondylitis. In another patient, a recurrence of pars planitis was noted 14 months postoperatively. In both cases, remission was successfully achieved with the standard treatment.\u003c/p\u003e \u003cp\u003eSpearman's rank correlation analysis did not reveal any association between the occurrence of hyphema, cataract formation, or uveitis recurrence and higher IOP values or the need for antiglaucoma medications. The frequency of complications following CP is presented in Table\u0026nbsp;\u003cspan refid=\"Tab7\" class=\"InternalRef\"\u003e8\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab7\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 8\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eList of postoperative complications identified during the study.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eComplication\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003en\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003ePercentage\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMicrohyphema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e46,1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u0026uarr; IOP\u0026thinsp;\u0026gt;\u0026thinsp;21 mmHg\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e23,0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eCataract\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e23,0\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eRecurrence of UV\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e15,3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eHyphema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e15,3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eFlare photometry results after CP\u003c/h2\u003e \u003cp\u003eIn patients who underwent CP, a statistically significant reduction in mean flare photometry values was observed, when compared to preoperative levels. Preoperative flare photometry values showed a strong positive correlation with preoperative IOP values, as indicated by Spearman\u0026rsquo;s rank correlation coefficient (r\u0026thinsp;=\u0026thinsp;0.811). However, no such correlation was found between flare photometry and postoperative IOP. Table\u0026nbsp;\u003cspan refid=\"Tab8\" class=\"InternalRef\"\u003e9\u003c/span\u003e presents the flare photometry results before and after CP.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab8\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 9\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eMean flare photometry in UG. Comparison of preoperative and postoperative values using the Wilcoxon test.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eFlare photometry\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eMean\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eMin.\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eMax.\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eSD\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"4\" nameend=\"c9\" namest=\"c6\"\u003e \u003cp\u003eWilcoxon signed-rank test\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003ePairs\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003en\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003ez\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003ep\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003ePre\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e18,03\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7,30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e26,00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e6,16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e10,25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6,90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e15,30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2,29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e1m \u0026amp; pre\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3,18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0,0015\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e9,77\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5,20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e15,10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2,60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3m \u0026amp; pre\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3,12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0,0018\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6m\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e9,73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6,10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e16,00\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2,66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e6m \u0026amp; pre\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3,41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e0,0007\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eAs previously mentioned, UG is particularly challenging to manage due to the necessity of simultaneous treatment of the underlying inflammatory disease. Rapid and effective control of intraocular inflammation is key to achieving successful outcomes. However, this remains difficult, as corticosteroids, which are the mainstay of anti-inflammatory therapy, can contribute to the increase in IOP.\u003c/p\u003e \u003cp\u003eChronic disruption of the BAB, commonly observed in this patient\u0026rsquo;s population, not only increases the risk of postoperative complications, but may also contribute to the late surgical failure, for instance, due to excessive scarring. For these reasons, in recent years, there has been an increasing shift towards MIGS, particularly bleb-less procedures, in the treatment of UG [\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e, \u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe conducted study confirmed the high efficacy of CP in the treatment of UG, with the mean IOP reduction of 66% and 64% at 12 and 18 months postoperatively, respectively. Throughout the entire follow-up period, only 1 patient required an introduction of IOP-lowering therapy. This patient had the longest diagnosis of both UG and the underlying systemic disease within the study group. At 1.5 years postoperatively, 84% of patients achieved TS for IOP\u0026thinsp;\u0026lt;\u0026thinsp;21 mmHg and IOP\u0026thinsp;\u0026lt;\u0026thinsp;18 mmHg.\u003c/p\u003e \u003cp\u003eCP also proved to be a safe surgical approach for UG management. No sight-threatening complications were recorded. Hyphema or microhyphema were observed in 61.4% of patients on the first postoperative day. As demonstrated by Grieshaber et al. in their 2011 study, the presence of hyphema shortly after canaloplasty correlates with greater long-term surgical success and should not be considered a complication [\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e]. The cumulative probability of achieving IOP\u0026thinsp;\u0026le;\u0026thinsp;16 mmHg without the need for medication was 87% (95% CI; 0.76\u0026ndash;0.98) in patients who developed microhyphema/hyphema on the first postoperative day, compared to only 21% (95% CI; 0.04\u0026ndash;1.0) in patients whose anterior chamber remained clear. Additionally, patients with intraoperative or early postoperative hyphema/microhyphema were less likely to require goniopuncture during follow-up.\u003c/p\u003e \u003cp\u003eCataract development or its progression was observed in 23% of patients. Although the chronic use of corticosteroids played a significant role in the development of this complication, its incidence was notably lower than that reported after filtering surgeries. For comparison, the Advanced Glaucoma Intervention Study (AGIS) found that the risk of cataract progression following trabeculectomy was 78% [\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e]. Similarly, in the study by Mills et al., 45% of all cataract cases occurred within the first 6 months postoperatively [\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eHusain et al. demonstrated that cataract surgery after trabeculectomy increases the risk of glaucoma surgery failure, with the risk being higher when the interval between trabeculectomy and cataract surgery is shorter. If cataract surgery was performed within 6 months after trabeculectomy, the risk of failure for the latter was 3.00 (95% CI; 1.11\u0026ndash;8.14). In contrast, when the interval between procedures was extended to 2 years, the risk decreased to 1.32 (95% CI; 1.02\u0026ndash;1.69) [\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe incidence of uveitis recurrence after surgery was not higher than before the procedure. During the study, recurrence was observed in 2 patients. No patient showed signs of uveitis within the first 11 months postoperatively. The procedure even led to a statistically significant reduction in the mean flare photometry values compared to preoperative levels. The type of uveitis did not appear to influence surgical outcomes.\u003c/p\u003e \u003cp\u003eUG is a rare condition with a heterogeneous etiology, which is why there is no standardized therapeutic protocol, and each case requires an individual approach. Due to this variability, there are only a few studies evaluating the effectiveness of different treatment approaches in this type of glaucoma. This study, which includes 13 eyes, is one of the largest assessing CP outcomes in UG.\u003c/p\u003e \u003cp\u003eLommatzsch et al. retrospectively evaluated the efficacy of CP in 12 eyes with UG. 2 years after surgery, the mean IOP reduction was 46.4%, accompanied by a 77% reduction in the number of antiglaucoma medications. No statistically significant differences in flare photometry measurements were observed between preoperative values and those recorded 1 month postoperatively. However, at 3 months postoperatively, a decrease in flare photometry was noted, which then remained stable up to 12 months [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. TS rate for IOP\u0026thinsp;\u0026le;\u0026thinsp;21 mmHg at 2 years after surgery was 58%, which was lower than in our study (87.5%). This difference may be attributed to the differences in patient profiles between the studies. In the study by Lommatzsch et al., most of included eyes had idiopathic uveitis, with some previously operated cases, and a mean UG duration twice as long as in the present study (52.4\u0026thinsp;\u0026plusmn;\u0026thinsp;47.6 months vs. 24.47\u0026thinsp;\u0026plusmn;\u0026thinsp;27.39 months) [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]. In the current study, the most frequent diagnoses were HLA-B27 (+) uveitis and FHU. Also, only previously unoperated eyes were included.\u003c/p\u003e \u003cp\u003eIn another study, Brusini et al. evaluated CP outcomes in 9 eyes with steroid-induced glaucoma (SIG). None of the patients had uveitis; steroid therapy was administered due to severe allergy or as prophylaxis against graft rejection following keratoplasty. At 1 year postoperatively, the mean IOP decreased by 55%, while the number of antiglaucoma eye drops was reduced by 95.3%. Additionally, 100% of the eyes achieved TS for both predefined IOP thresholds (\u0026le;\u0026thinsp;21 mmHg and \u0026le;\u0026thinsp;16 mmHg). The most common complication was microhyphema, occurring in 22% of eyes. 1 eye experienced transient hypotony, but IOP returned to normal within 1 week, without any intervention and without any negative impact on the final BCVA [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eKalin-Hajdu et al. analised phaco-CP (5 eyes) and CP (8 eyes) in 9 patients with UG. At 2.5 years postoperatively, 84.2% of patients achieved IOP control, defined as IOP\u0026thinsp;\u0026gt;\u0026thinsp;6 mmHg and \u0026lt;\u0026thinsp;21 mmHg, along with a minimum 20% reduction from the baseline values. Among these, 73.7% of patients did not require pharmacologic treatment. The mean IOP reduction was 55.9%, accompanied by a 94.4% reduction in the number of antiglaucoma medications. Goniopuncture was required in 42.1% of cases. The authors recorded 1 case of prolonged hypotony with hypotonic maculopathy following goniopuncture; however, all other complications were transient and did not pose a threat to vision [\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eA comparative summary of the studies evaluating the efficacy of CP in UG and SIG is presented in Table\u0026nbsp;\u003cspan refid=\"Tab9\" class=\"InternalRef\"\u003e10\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab9\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 10\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eEfficacy of CP in UG and SIG.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"4\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eLommatzsch 2016 [\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e]\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eBrusini 2018 [\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e]\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003en\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eType of glaucoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUG\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eSIG\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eIOP pre\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e27.0\u0026thinsp;\u0026plusmn;\u0026thinsp;12.2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e30.7\u0026thinsp;\u0026plusmn;\u0026thinsp;7.2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u0026darr; IOP %\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e55\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e45\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003ePre med\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e2.7\u0026thinsp;\u0026plusmn;\u0026thinsp;1.1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e4.3\u0026thinsp;\u0026plusmn;\u0026thinsp;0.7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u0026darr;med.%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e95.3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e77.8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eTS\u0026thinsp;\u0026le;\u0026thinsp;21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eTS\u0026thinsp;\u0026le;\u0026thinsp;18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eTS\u0026thinsp;\u0026le;\u0026thinsp;15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e1y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003e2y\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"4\" nameend=\"c4\" namest=\"c1\"\u003e \u003cp\u003eComplications\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eCataract\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e6,4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eHyphema\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003e\u0026uarr; IOP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eWTR astigmatism\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eHypotony\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c2\" namest=\"c1\"\u003e \u003cp\u003eDescemet detachment\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e-\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e"},{"header":"Summary","content":"\u003cp\u003eThe conducted study confirmed the efficacy of canaloplasty in the treatment of UG. The procedure leads to a significant reduction in IOP and the number of antiglaucoma medications required postoperatively. Furthermore, canaloplasty has been shown to be a safe procedure, with postoperative complications being transient and not posing a threat to the patient\u0026rsquo;s vision.\u003c/p\u003e \u003cp\u003eCanaloplasty appears to be a promising therapeutic alternative for the patients with UG. However, the presence of an open angle without anterior synechiae is a prerequisite for performing the procedure.\u003c/p\u003e \u003cp\u003eThe limitations of this study include its single-center design, lack of randomization, small sample size, and relatively short follow-up period.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eM.Ł-G and M.P prepared the draft of the manuscriptA.K and T.G were responsible for data acquisition and interpretationM.G and J.D were responsible for data analysisM.P and J.D prepared figuresA.K and JP.S reviewed the manuscript\u003c/p\u003e\n\u003ch3\u003e\u003cu\u003eAcknowledgements\u003c/u\u003e\u003c/h3\u003e\n\u003ch3\u003eNone of the authors has no financial interest concerning presented subject.\u003c/h3\u003e\n\u003cp\u003e\u003cu\u003eClinical trial number\u003c/u\u003e: not applicable\u003c/p\u003e\n\u003cp\u003eNo Funding was received to conduct this study\u003c/p\u003e\n\u003cp\u003eAll patients signed a consent form prior to undergoing the procedure. The study was conducted in accordance with the Declaration of Helsinki. The study received approval of the Ethics Committee\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eMoorthy, R.S., et al., \u003cem\u003eGlaucoma associated with uveitis.\u003c/em\u003e Surv Ophthalmol, 1997. 41(5): p. 361-94.\u003c/li\u003e\n \u003cli\u003eMunoz-Negrete, F.J., et al., \u003cem\u003eCurrent Approach in the Diagnosis and Management of Uveitic Glaucoma.\u003c/em\u003e Biomed Res Int, 2015. 2015: p. 742792.\u003c/li\u003e\n \u003cli\u003eNeri, P., A. Azuara-Blanco, and J.V. Forrester, \u003cem\u003eIncidence of glaucoma in patients with uveitis.\u003c/em\u003e J Glaucoma, 2004. 13(6): p. 461-5.\u003c/li\u003e\n \u003cli\u003eSung, V.C. and K. Barton, \u003cem\u003eManagement of inflammatory glaucomas.\u003c/em\u003e Curr Opin Ophthalmol, 2004. 15(2): p. 136-40.\u003c/li\u003e\n \u003cli\u003eDaniel, E., et al., \u003cem\u003eRisk of Ocular Hypertension in Adults with Noninfectious Uveitis.\u003c/em\u003e Ophthalmology, 2017. 124(8): p. 1196-1208.\u003c/li\u003e\n \u003cli\u003eFini, M.E., et al., \u003cem\u003eSteroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.\u003c/em\u003e Prog Retin Eye Res, 2017. 56: p. 58-83.\u003c/li\u003e\n \u003cli\u003eFeiner, L., J.R. Piltz-Seymour, and S. Collaborative Initial Glaucoma Treatment, \u003cem\u003eCollaborative Initial Glaucoma Treatment Study: a summary of results to date.\u003c/em\u003e Curr Opin Ophthalmol, 2003. 14(2): p. 106-11.\u003c/li\u003e\n \u003cli\u003eMeier-Gibbons, F., M.S. Berlin, and M. Toteberg-Harms, \u003cem\u003eInfluence of new treatment modalities on adherence in glaucoma.\u003c/em\u003e Curr Opin Ophthalmol, 2019. 30(2): p. 104-109.\u003c/li\u003e\n \u003cli\u003eMusch, D.C., et al., \u003cem\u003eVisual field progression in the Collaborative Initial Glaucoma Treatment Study the impact of treatment and other baseline factors.\u003c/em\u003e Ophthalmology, 2009. 116(2): p. 200-7.\u003c/li\u003e\n \u003cli\u003eYamanaka, O., et al., \u003cem\u003ePathobiology of wound healing after glaucoma filtration surgery.\u003c/em\u003e BMC Ophthalmol, 2015. 15 Suppl 1: p. 157.\u003c/li\u003e\n \u003cli\u003eGedde, S.J., et al., \u003cem\u003eTreatment Outcomes in the Primary Tube Versus Trabeculectomy Study after 3 Years of Follow-up.\u003c/em\u003e Ophthalmology, 2020. 127(3): p. 333-345.\u003c/li\u003e\n \u003cli\u003eGedde, S.J., et al., \u003cem\u003eTreatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up.\u003c/em\u003e Am J Ophthalmol, 2012. 153(5): p. 789-803 e2.\u003c/li\u003e\n \u003cli\u003eYamanaka, O., et al., \u003cem\u003ePathobiology of wound healing after glaucoma filtration surgery.\u003c/em\u003e BMC Ophthalmol, 2015. 15 Suppl 1: p. 157.\u003c/li\u003e\n \u003cli\u003eSouissi, K., et al., \u003cem\u003e[Trabeculectomy for the management of uveitic glaucoma].\u003c/em\u003e J Fr Ophtalmol, 2006. 29(2): p. 153-6.\u003c/li\u003e\n \u003cli\u003eKaburaki, T., et al., Initial trabeculectomy with mitomycin C in eyes with uveitic glaucoma with inactive uveitis. Eye (Lond), 2009. 23(7): p. 1509-17.\u003c/li\u003e\n \u003cli\u003eMatlach, J., et al., \u003cem\u003eTrabeculectomy versus canaloplasty (TVC study) in the treatment of patients with open-angle glaucoma: a prospective randomized clinical trial.\u003c/em\u003e Acta Ophthalmol, 2015. 93(8): p. 753-61.\u003c/li\u003e\n \u003cli\u003eNetland, P.A., et al., \u003cem\u003eRandomized, prospective, comparative trial of EX-PRESS glaucoma filtration device versus trabeculectomy (XVT study).\u003c/em\u003e Am J Ophthalmol, 2014. 157(2): p. 433-440 e3.\u003c/li\u003e\n \u003cli\u003eNouri-Mahdavi, K., et al., \u003cem\u003eOutcomes of trabeculectomy for primary open-angle glaucoma.\u003c/em\u003e Ophthalmology, 1995. 102(12): p. 1760-9.\u003c/li\u003e\n \u003cli\u003eWagner, F.M., et al., \u003cem\u003eEfficacy and safety of XEN(R)-Implantation vs. trabeculectomy: Data of a \u0026quot;real-world\u0026quot; setting.\u003c/em\u003e PLoS One, 2020. 15(4): p. e0231614.\u003c/li\u003e\n \u003cli\u003eBull, H., et al., Three-year canaloplasty outcomes for the treatment of open-angle glaucoma: European study results. Graefes Arch Clin Exp Ophthalmol, 2011. 249(10): p. 1537-45.\u003c/li\u003e\n \u003cli\u003eBrusini, P., \u003cem\u003eCanaloplasty in open-angle glaucoma surgery: a four-year follow-up.\u003c/em\u003e ScientificWorldJournal, 2014. 2014: p. 469609.\u003c/li\u003e\n \u003cli\u003eLiu, H., et al., \u003cem\u003eSafety and efficacy of canaloplasty versus trabeculectomy in treatment of glaucoma.\u003c/em\u003e Oncotarget, 2017. 8(27): p. 44811-44818.\u003c/li\u003e\n \u003cli\u003eVastardis, I., et al., \u003cem\u003eEstimation of risk-benefit ratio and comparison of post-operative efficacy results between trabeculectomy and canaloplasty.\u003c/em\u003e Eur J Ophthalmol, 2021. 31(3): p. 1405-1412.\u003c/li\u003e\n \u003cli\u003eWatson, P.G., et al., \u003cem\u003eThe complications of trabeculectomy (a 20-year follow-up).\u003c/em\u003e Eye (Lond), 1990. 4 ( Pt 3): p. 425-38.\u003c/li\u003e\n \u003cli\u003eSzymor J, J.P., \u003cem\u003eFlaremetry measurement of blood-aqueousbarrier breakdown after canaloplasty combined with phacoemulsification versus phacoemulsification in patients with secondary open angle glaucoma.\u003c/em\u003e Klinika oczna/Acta Ophthalmologica Polonica, 2018. 120(3): p. 133-138.\u003c/li\u003e\n \u003cli\u003eGrieshaber, M.C., et al., Postoperative microhyphema as a positive prognostic indicator in canaloplasty. Acta Ophthalmol, 2013. 91(2): p. 151-6.\u003c/li\u003e\n \u003cli\u003eThe Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. Am J Ophthalmol. 2000 Oct;130(4):429-40\u003c/li\u003e\n \u003cli\u003eMills, K.B., \u003cem\u003eTrabeculectomy: a retrospective long-term follow-up of 444 cases.\u003c/em\u003e Br J Ophthalmol, 1981. 65(11): p. 790-5.\u003c/li\u003e\n \u003cli\u003eHusain, R., et al., \u003cem\u003eCataract surgery after trabeculectomy: the effect on trabeculectomy function.\u003c/em\u003e Arch Ophthalmol, 2012. 130(2): p. 165-70.\u003c/li\u003e\n \u003cli\u003eLommatzsch, C., et al., \u003cem\u003eCanaloplasty in patients with uveitic glaucoma: a pilot study.\u003c/em\u003e Graefes Arch Clin Exp Ophthalmol, 2016. 254(7): p. 1325-30.\u003c/li\u003e\n \u003cli\u003eBrusini, P., C. Tosoni, and M. Zeppieri, \u003cem\u003eCanaloplasty in Corticosteroid-Induced Glaucoma. Preliminary Results.\u003c/em\u003e J Clin Med, 2018. 7(2).\u003c/li\u003e\n \u003cli\u003eKalin-Hajdu, E., et al., \u003cem\u003eOutcome of viscodilation and tensioning of Schlemm\u0026apos;s canal for uveitic glaucoma.\u003c/em\u003e Can J Ophthalmol, 2014. 49(5): p. 414-9\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Canaloplasty, Non-penetrating glaucoma surgery, Uveitic glaucoma, Schlemm’s canal surgery","lastPublishedDoi":"10.21203/rs.3.rs-8603369/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8603369/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eIntroduction: Uveitic glaucoma (UG) is a type of secondary glaucoma in which elevated intraocular pressure (IOP) and subsequent optic nerve damage result from a chronic inflammation of the uvea. UG is estimated to occur in approximately 20% of patients with uveitis. Due to its complex etiology UG treatment requires a highly personalized approach. In recent years, minimally invasive glaucoma surgery (MIGS) procedures, such as canaloplasty (CP), have gained recognition for their potential to effectively reduce IOP while minimizing complications associated with traditional filtration surgeries. The aim of this study was to evaluate the efficacy and safety of canaloplasty in patients with UG.\u003c/p\u003e\n\u003cp\u003eMaterials and Methods: This prospective study included 15 eyes with UG that received 360° ab externo canaloplasty. The main indication for surgery was the failure of maximum tolerated medical therapy. Control check-ups were conducted pre-operatively and in an 18-month follow-up time. Study endpoints involved reduction in IOP values and in the number of glaucoma medications after the intervention.\u003c/p\u003e\n\u003cp\u003eResults: CP led to a significant 64 % reduction in IOP (14.44 ± 3.54 mmHg) from the preoperative baseline. The number of medications decreased significantly by 94%. Complete success (IOP \u0026lt; 18 mmHg) was achieved in 84% of patients, while qualified success (IOP \u0026lt; 21 mmHg) was observed in 92%. No severe complications were reported. The most common postoperative findings were microhyphema (46.1%) and cataract formation (23%). A recurrence of uveitis was noted in two cases (15.3%) but was successfully managed. Flare photometry measurements indicated a significant reduction in intraocular inflammation postoperatively.\u003c/p\u003e\n\u003cp\u003eConclusions: Canaloplasty proved to be an effective and safe surgical option for UG patients.\u003c/p\u003e","manuscriptTitle":"Canaloplasty in the Treatment of Uveitic Glaucoma – Results of an 18-Month Follow-up","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-02-05 09:17:25","doi":"10.21203/rs.3.rs-8603369/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"4e2355ab-e34e-4b3a-99d2-413b974337c2","owner":[],"postedDate":"February 5th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2026-02-11T15:41:50+00:00","versionOfRecord":[],"versionCreatedAt":"2026-02-05 09:17:25","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8603369","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8603369","identity":"rs-8603369","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}